are the most widely used immunomodulatory drugs for treatment of multiple sclerosis (MS). The development of neutralizing antibodies (NABs) against IFN-b is one of the main reasons for treatment failure. While formulation of the drug has a proven impact on the development of NABs, the genetic predisposition to develop antibodies is poorly understood. We performed genome-wide single-nucleotide polymorphism (SNP) genotyping in 362 MS patients of whom 178 had developed and 184 had not developed antibodies on IFN-b therapy. Four candidate SNPs were validated in an independent cohort of 350 antibodypositive and 468 antibody-negative MS patients. One SNP within the human leucocyte antigen (HLA) region (rs9272105, P-value: 3.56 Â 10
Introduction
Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system. 1, 2 Disease usually sets on in young adults and over time leads to severe disability in a significant proportion of patients. 3 Although the cause of MS is still unknown, many findings support an autoimmune pathogenesis of disease influenced by genetic and environmental factors. [4] [5] [6] [7] Interferons-b (IFN-b) are approved for treatment of clinically isolated syndrome, relapsing remitting and secondary chronic progressive MS. Treatment with IFN-b has a profound impact on inflammatory activity in the central nervous system as determined by magnetic resonance imaging and decreases relapse rates by 30-50%. 8 Owing to their excellent safety profile, IFN-b are the most widely prescribed immunomodulatory drugs for treatment of MS. However, up to 30% of patients on therapy develop an antibody response to IFN-b (binding antibodies), most of them with neutralizing activity (neutralizing antibodies, NABs). [9] [10] [11] The development of persisting NABs is associated with a loss of in vivo bioactivity and treatment efficacy of the drug. 12 Accordingly, patients who develop persistent NABs show a higher relapse rate, magnetic resonance imaging activity and possibly disease progression than those who do not. [13] [14] [15] [16] According to current guidelines, these patients do not benefit from therapy and IFN-b therapy is no longer recommended. [17] [18] [19] It is well established that IFN-b formulation and the mode of application strongly influence the development of NABs. However, it is conceivable that the immune system of the treated patient is of central importance for the development of a humoral immune response to IFN-b. Given the impact of genetic factors for mounting immune responses to self-and foreign antigens, it is likely that the formation of anti-IFN-b antibodies is influenced by genetic factors. Determining these genetic determinants might allow to identify patients at risk to develop NABs and eventually influence treatment decisions in these patients.
We recently demonstrated that the formation of antibodies against IFN-b is strongly associated with the human leucocyte antigen (HLA) alleles DRB1*0401 and HLA-DRB1*0408 (ref. 20) . A genome-wide association study, however, which correlates genetic markers with the antibody response to IFN-b therapy in MS patients, has not been performed so far. To identify additional genes that influence antibody development, we performed a genome-wide analysis in MS patients on IFN-b therapy.
Materials and methods

Patients
Patients with MS according to the criteria of McDonald or Poser, predominantly of northern European decent, and treated with IFN-b were recruited in Germany in a multicenter study. All patients were treated with IFN-b for at least 5 months (mean treatment duration 50 months) and demonstrated a relapsing remitting or secondary progressive course, when the patients were enrolled in the study. The initial study group included 46 MS patients with binding, 138 MS patients with neutralizing antibodies and 188 MS patients who had not developed antibodies to IFN-b. The validation cohort consisted of 187 patients with binding, 151 patients with neutralizing, 12 patients with positive antibody reactivity, but missing MxA values. A total of 468 patients had not developed antibodies against IFN-b. Written consent was obtained from all patients. The study was approved by the ethics committees of the Universities of Düsseldorf and Munich. Written informed consent was obtained from all patients.
Single-nucleotide polymorphism genotyping Genome-wide genotyping was performed by HumanCNV 370-Duo_v1-0 BeadChip (Illumina, San Diego, CA, USA) arrays, which covered about 317.000 single-nucleotide polymorphism (SNP) loci from the entire human genome. Genotyping was performed according to the standard protocols of the manufacturer for the Infinium II process.
Genotyping of smaller batches of SNPs, as required for replication in a second independent sample, was performed by using a MassArray system (Sequenom, San Diego, CA, USA). Primer selection, multiplexing and assay design were done using the company's web-based tool (mysequenom. com) with the iplex option. All required oligonucleotide primers were supplied locally (Metabion, Martinsried, Germany). Extension products were produced by Sequenom's homogeneous mass-extension process and their mass was determined by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) on a highly automated system (Sequenom). Genotype calling was done using Sequenom's software MassArray Typer Ver. 3.4.
Assays for binding and NABs
To detect antibodies against IFN-b, we performed a standardized capture enzyme-linked immunosorbent assay as described. 21 Defined positive and negative serum samples were included in each assay to obtain a standard curve for comparison of different assays. The standard curve ranged from 100% (highest positive control) to 0% (no antibodies). Serum positivity of all tested samples was normalized on the basis of these standard curves. Reactivity above 25% of the highest positive control was considered to be antibody positive (the cutoff value corresponded to the median of 50 control donors þ 5 s.d.).
The biological in vivo activity of IFN-b was measured by MX1 (MxA) gene expression with TaqMan real-time PCR. 22 Twelve hours after IFN-b injection, blood samples were drawn from subjects and mRNA was isolated according to the manufacturer's instructions. TaqMan reverse-transcription reagents (Applied Biosystems, Foster City, CA, USA) were used to convert mRNA to cDNA. cDNA levels were detected with ABI's GeneAmp via the protocols described. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase was used as internal control. Normalization was done according to the DDCt method. In each assay, the same positive and negative samples were included to ensure the quality of the assay. Antibodies were considered biologically active when the MX1 (MxA) induction was decreased by 450% compared with newly treated antibody-negative control donors.
Statistics
Genome-wide association analysis was performed using PLINK V1.06 and R V2.9.2. Standard criteria for quality control were used, that is minimum call rates per SNP and individual were set to 0.98, and a threshold of P ¼ 1 Â 10
À5
for deviation from Hardy-Weinberg equilibrium was imposed. Genetic outliers were defined as individuals whose position on at least one of the first two multidimensional scaling axes differed 44 s.d. from the mean of the corresponding axis. Eight patients differed 44 s.d. from the mean of the corresponding axes in the QQ plot, and in SNPs associated with anti-interferon-b antibodies two patients clinical data were insufficient. Therefore, 10 patients were excluded from further analysis. The total genotyping rate in the remaining individuals was 99.75% and the genomic inflation factor l was 1.00072 (Supplementary Figure 1) . The underlying genetic model was a dosage model, mimicking the Armitage test for trend. Quantitative traits were normalized using the inversenormal transformation method. Covariates added were age at sampling, sex, the course of disease as well as the first two axes resulting from the multidimensional scaling analysis of the identity-by-state matrix to take population stratification into account. For quantitative traits, we used linear regression. Testing for interactions was again done in the framework of linear models. Genome-wide significance was assumed when the P-values reached a threshold of 5 Â 10 À8 .
Results
A total of 178 patients who developed binding or NABs to IFN-b and 184 patients who did not develop antibodies on IFN-b therapy were genotyped for 4300.000 SNPs genomewide. Demographics, treatment and details on antibody testing are given in Table 1 . Figure 1 demonstrates the association of SNPs with antibody formation in our initial genome-wide association study. From these results, we selected four SNPs found to be associated with antibody titer with a P-value o10
À5
(Supplementary Table 1 ). These four candidate SNPs were validated in an independent sample of 350 antibodypositive and 468 antibody-negative patients, raising the total sample size to 528 antibody-positive and 652 antibodynegative patients. In the combined sample, one SNP within the HLA region (rs9272105, P-value: 3.56 Â 10 Table 1 ). The association of rs9272105 and rs4961252 with antibody response against IFN-b was consistently found in both the initial and the validation sample (Figure 2 ; Supplementary Table 1 ). Figure 3 shows the distribution of P-values found in our initial genome-wide association around rs9272105 (Figure 3a ) and rs4961252 (Figure 3b) . The non-HLA-SNP rs4961252 is located in an intergenic region of chromosome 8q24.3. The most proximate genes are DENN/MADD domain containing 3 (DENND3) at a distance of 33.8 kb in the downstream direction and protein tyrosine kinase 2 (PTK2) at a distance of 93.6 kb in the upstream direction.
One SNP (rs1375713) failed quality control in the replication genotyping and another SNP (rs7626997) Abbreviations: IFN, interferons; i.m., intramuscularly; s.c., subcutaneously. % Antibody reactivity, antibody titers were determined by enzyme-linked immunosorbent assay and normalized to reference sera (100%, high titer; 0% no antibodies), %MxA induction; antibody titers were determined by real-time quantitative reverse transcription polymerase chain reaction and normalized to control samples (100%, MxA levels in newly IFN-b-treated individuals, 0% MxA levels in individuals not treated with IFN-b).
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showed no significant association with development of antibodies in the replication or the combined sample (Supplementary Table 1 ). The SNP within the HLA region, rs9272105, explains 3.5% variance of the anti-IFN-b antibody response; the non-HLA-SNP rs4961252 explains 2.6%. The result was independent of the IFN-b formulation used.
A total of 634 patients were typed for HLA-class II alleles; 92 of these patients carried the HLA-DR*0401 or *0408 alleles, which were shown to be associated with an antibody response to IFN-b. 20 Within these 634 patients, the HLA-SNP rs9272105 was associated with antibody titer with a P-value of 3.69 Â 10
À6
, the HLA-DR*0401 or *0408 alleles with 7.74 Â 10
À5 . Linear regression analysis demonstrated an independent effect of rs9272105, which is situated about 5 kb upstream of the HLA-DQA1 gene in the intergenic region between the HLA-DRB1 and HLA-DQA1 genes, and the HLA-DR*0401 or *0408 alleles (P-value: 1.95 Â 10 À4 ). We found no interaction between the genome-wide significant SNPs (rs9272105 and rs4961252) in our study and the 
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HLA-DR*0401 or *0408 alleles. This finding indicates an additive effect of the SNPs described in our study and the previously reported HLA-DR*0401 or *0408 alleles (Supplementary Table 2 ). Based on the distribution of the SNPs rs4961252, rs9272105 and the two HLA alleles HLA-DRB1*0401 and 0408, an individual risk for MS patients to develop antibodies to IFN-b can be calculated ( Table 2 ). The combined odds ratio for both SNPs HLA-DRB1*0401/0408 is 5.32. Individuals who carry the protective SNPs rs4961252-AA and rs9272105-AA and are HLA-DRB1*0401 or 0408 negative carry a low risk to develop antibodies during IFN-b therapy. In contrast, individuals with the rs4961252-GG and rs9272105-GG genotypes and the HLA-DRB1*0401 or 0408 allele, are highly prone to develop antibodies to IFN-b.
Discussion
Multiple sclerosis is a chronic disease of the central nervous system that affects more than one million individuals worldwide. It is a disease of young adults and over time leads to severe disability in the majority of patients. IFN-b is an effective treatment of MS and several hundred thousand patients are on long-term IFN-b therapy. However, a ) between each single-nucleotide polymorphism (SNP) and rs9272105 and rs4961252, respectively, was calculated from our sample data and is represented by sliding hues of red. The recombination rates given in centimorgans per million bases are shown in light blue and are based on the 1000 Genomes Project data. These plots were generated using SNAP Version 2.
(ref. 29).
SNPs associated with anti-interferon-b antibodies significant proportion of patients develop NABs to IFN-b. The rate of patients, who develop antibodies differs between the IFN-b formulations. 23 While NABs are only observed in 5-10% of patients treated with IFN-b1a intramuscularly once weekly (Avonex), up to 30% of patients develop NABs treated with IFN-b1a subcutaneously. three times a week (Rebif) and IFN-b1b s.c every second day (Betaferon/ Betaseron). Unfortunately, the later IFN-b formulations seem to be more effective to suppress clinical and paraclinical disease activity, 24, 25 if the patient does not develop NABs.
High titer of NABs abolish the in vivo bioactivity of the drug and the treatment effects with respect to clinical and paraclinical outcome parameters. 13, [15] [16] [17] These antibodies persist even years after cessation of IFN-b therapy. 26 As a result, a significant number of patients will be exposed to a treatment that is no longer effective and have to be switched to other therapies. Many patients, however, despite high titer of NABs remain on therapy, which puts them at risk for disease progression. Moreover, hundreds of millions of dollars are spent each year on ineffective IFN-b therapy.
Knowledge on the genetic determinants for the development of NABs would allow to identify patients at high risk before the initiation of IFN-b therapy. In these patients, treatment with less immunogenic IFN-b formulations or other immunomodulatory drugs would be more appropriate. In contrast, patients with low risk to develop antibodies could be exposed to the more immunogenic but more effective high-dose IFN-b treatment. 24, 25 Therefore, we performed a genome-wide association study to identify genes predisposing to antibody development in patients on IFN-b therapy. We identified one SNP (rs9272105) within the HLA complex on chromosome 6 and one SNP (rs4961252) on chromosome 8q24.3 that demonstrate a genome-wide significant association with anti-IFN-b antibody development. The association of rs9272105 and rs4961252 with antibody response against IFN-b was consistently found in both, the initial and the validation sample (Figure 2 ; Supplementary Table 1) . Besides the influence of the HLA-SNP (rs9272105), the non-HLA-SNP (rs4961252) exerts its own additive effect. In addition, a linear regression analysis points to an independent effect of rs9272105-located within the HLA-region-and the HLA-DR*0401 and *0408 alleles, which were already described as risk factors for the development of an anti-IFN-b antibody response before 20 (Supplementary Table 2 ). It is well established that HLA alleles can influence the development of antibody responses to self-and foreign proteins. HLA class II alleles are important for the activation of CD4 þ T helper cells, which themselves are central for the generation of B-cell and antibody responses to protein antigens. It is, therefore, conceivable that the SNP in the intergenic region between the HLA-DRB1 and HLA-DQA1 genes impacts on antigen processing, T-cell and B-cell activation and eventually antibody formation.
The biological role of the non-HLA-SNP rs4961252 located in an intergenic region of chromosome 8q24.3 for antibody formation remains uncertain. Little is known about the two proximate genes DENN/MADD domain containing 3 (DENND3, 33.8 kb downstream) and protein tyrosine kinase 2 (PTK2, 93.6 kb in the upstream). DENND3 contains a WD40 domain, which is one of the most abundant identifiable protein domains throughout diverse species and is frequently found in proteins involved in a wide variety of cellular processes like signal transduction, premRNA processing, cell-cycle control, apoptosis or cytoskeleton assembly. The protein encoded by PTK2 constitutes a cytoplasmic protein tyrosine kinase, which is a member of the focal adhesion kinase superfamily. It is a key molecule in intracellular signaling, interacting with numerous proteins. PTK2, also referred to as focal adhesion kinase, has a major role in various pathways among which is the ability of cells to sense and respond efficiently to changes in the microenvironment. 27 How these genes possibly influence the development of NABs remains elusive. Frequency and number of individuals that developed antibodies based on the HLA-DRB1 alleles and the genotypes of the SNPs rs9272105 and rs4961252. The total number of patients with a particular combination is shown in parenthesis.
SNPs associated with anti-interferon-b antibodies
The identification of two SNPs associated with the development of IFN-b together with the previously reported and confirmed HLA-DRB1*401 and 0408 alleles allows to calculate the individual risk of patients to develop antibodies before the initiation of therapy. The individual risk calculated on the basis of these SNPs and HLA alleles varies from 0.19 to 0.77 (Table 2 ). Introducing testing of these SNPs in clinical practice would allow to predict the individual risk of patients to develop antibodies and support physicians in their treatment decisions. While patients with low risk could easily be exposed to not only more immunogenic but also more effective IFN-b formulations, those with high risk would be better provided with a low immunogenic IFN-b formulation or other therapeutic options. Testing would avoid exposing patients to therapies, which would eventually render ineffective, thus making MS treatment more efficient and avoiding non-necessary costs due to ineffective therapies.
